GILD

SEC source: 0001127602-23-009986 · form4.xml · derivative · entry 6

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,312

Underlying: Common Stock · 16,665 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009986 · form4.xml · derivative · entry 5

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,647

Underlying: Common Stock · 7,999 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-009986 · form4.xml · derivative · entry 4

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,646

Underlying: Common Stock · 3,455 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-009986 · form4.xml · nonDerivative · entry 3

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,256

SEC source: 0001127602-23-009986 · form4.xml · nonDerivative · entry 2

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,584

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-009986 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-010012 · form4.xml · derivative · entry 7

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,095

Underlying: Common Stock · 215,095 shares

Expires 2033-03-10

F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-010012 · form4.xml · derivative · entry 6

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,933

Underlying: Common Stock · 47,170 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-010012 · form4.xml · derivative · entry 5

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,763

Underlying: Common Stock · 10,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-010012 · form4.xml · derivative · entry 4

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,563

Underlying: Common Stock · 19,488 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-23-010012 · form4.xml · nonDerivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,766

SEC source: 0001127602-23-010012 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-010012 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-009787 · form4.xml · derivative · entry 3

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,442 shares

Expires 2023-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting.

SEC source: 0001127602-23-009787 · form4.xml · nonDerivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,442

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-008485 · form4.xml · derivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,051

Underlying: Common Stock · 11,362 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-008485 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359,495

SEC source: 0001127602-23-008485 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,337

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-008491 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,130

F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan.

F2 · price: Sale prices reported for the transactions reported here range from $79.60 to $80.34. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-23-006757 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376

F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2022 through February 15, 2023. The transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 16, 2022.

SEC source: 0001127602-23-006763 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,114

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2022 through February 15, 2023. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 16, 2022.

SEC source: 0001127602-23-006770 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,618

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2022 through February 15, 2023. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 16, 2022.

SEC source: 0001127602-23-003764 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,669

Underlying: Common Stock · 1,817 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-003764 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,242

SEC source: 0001127602-23-003764 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-003825 · form4.xml · derivative · entry 3

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,060

Underlying: Common Stock · 1,864 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-23-003825 · form4.xml · nonDerivative · entry 2

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,010

SEC source: 0001127602-23-003825 · form4.xml · nonDerivative · entry 1

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-23-002286 · form4.xml · nonDerivative · entry 3

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,738

SEC source: 0001127602-23-002286 · form4.xml · nonDerivative · entry 2

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,487

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2020. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001127602-23-002286 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,772

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021 and March 10, 2022. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-23-002284 · form4.xml · nonDerivative · entry 3

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,711

SEC source: 0001127602-23-002284 · form4.xml · nonDerivative · entry 2

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,955

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2020. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001127602-23-002284 · form4.xml · nonDerivative · entry 1

Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,855

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021 and March 10, 2022. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-23-002288 · form4.xml · nonDerivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 352,975

SEC source: 0001127602-23-002288 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,053

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2020. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors

SEC source: 0001127602-23-002288 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,406

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021 and March 10, 2022. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-23-002290 · form4.xml · nonDerivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,365

SEC source: 0001127602-23-002290 · form4.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,690

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2020. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001127602-23-002290 · form4.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,420

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021 and March 10, 2022. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-23-002292 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,956

SEC source: 0001127602-23-002292 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,283

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2020. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001127602-23-002292 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,013

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021 and March 10, 2022. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

SEC source: 0001127602-23-000216 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,556

F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-22-028356 · form4.xml · derivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,103.7725

Underlying: Common Stock · 26.349 shares

Expires not disclosed

F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.

F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.

F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

SEC source: 0001127602-22-027386 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,486

Underlying: Common Stock · 1,027 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-22-027386 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,215

SEC source: 0001127602-22-027386 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-22-027387 · form4.xml · derivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,308

Underlying: Common Stock · 990 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-22-027387 · form4.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,430